tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Troppmann C et al. | Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. | 2003 | Transplantation | pmid:12883205 |
| Therapondos G et al. | Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? | 2003 | Transplantation | pmid:12883220 |
| Cavaillé-Coll MW and Elashoff MR | Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. | 1998 | Transplantation | pmid:9448161 |
| Gjertson DW et al. | The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. | 1995 | Transplantation | pmid:8545861 |
| Fridell JA et al. | Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. | 2006 | Transplantation | pmid:16906038 |
| Boldt A et al. | The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. | 2006 | Transplantation | pmid:16906043 |
| Reutzel-Selke A et al. | Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. | 2003 | Transplantation | pmid:12811235 |
| Gaber AO et al. | Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. | 2013 | Transplantation | pmid:23423269 |
| Molano RD et al. | Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. | 2003 | Transplantation | pmid:12811239 |
| Guethoff S et al. | Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. | 2013 | Transplantation | pmid:23423270 |
| Miyakoshi S et al. | Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. | 2007 | Transplantation | pmid:17700155 |
| Huang E et al. | Alemtuzumab induction in deceased donor kidney transplantation. | 2007 | Transplantation | pmid:17984833 |
| Jain A et al. | Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. | 2014 | Transplantation | pmid:25285953 |
| Ericzon BG et al. | The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. | 1992 | Transplantation | pmid:1376501 |
| Gonwa TA et al. | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | 2001 | Transplantation | pmid:11773892 |
| Fisher RA et al. | A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. | 1998 | Transplantation | pmid:9884248 |
| Yates CJ et al. | Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. | 2013 | Transplantation | pmid:23902993 |
| Egidi MF and Gaber AO | Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. | 2003 | Transplantation | pmid:12605133 |
| Ciancio G et al. | Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. | 2011 | Transplantation | pmid:21107305 |
| Camirand G et al. | Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. | 2001 | Transplantation | pmid:11468532 |
| Squifflet JP et al. | Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. | 2001 | Transplantation | pmid:11468536 |
| Yu S et al. | Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. | 2006 | Transplantation | pmid:16421475 |
| Jurcevic S et al. | A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. | 1998 | Transplantation | pmid:9603168 |
| Borrows R et al. | Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. | 2006 | Transplantation | pmid:16421488 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. | 2002 | Transplantation | pmid:12490779 |
| Shapiro AM et al. | Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. | 2002 | Transplantation | pmid:12490784 |
| Shaffer D et al. | Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). | 1995 | Transplantation | pmid:7535958 |
| Andries S et al. | Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. | 2001 | Transplantation | pmid:11477351 |
| Ho ET et al. | Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. | 2013 | Transplantation | pmid:23542469 |
| Taler SJ et al. | Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. | 1996 | Transplantation | pmid:8970613 |
| Porrini E et al. | Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. | 2008 | Transplantation | pmid:18431233 |
| Veroux M et al. | Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. | 2012 | Transplantation | pmid:22298033 |
| Naesens M et al. | Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. | 2008 | Transplantation | pmid:18431234 |
| Roelen DL et al. | Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. | 1993 | Transplantation | pmid:7687397 |
| MacDonald AS | Management strategies for nephrotoxicity. | 2000 | Transplantation | pmid:10910262 |
| Reyes J et al. | Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. | 2000 | Transplantation | pmid:10910279 |
| Higgins RM et al. | Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. | 2000 | Transplantation | pmid:10836393 |
| Cantarovich D et al. | Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. | 2005 | Transplantation | pmid:15714172 |
| Yamauchi A et al. | Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. | 2002 | Transplantation | pmid:12352921 |
| Nguyen L et al. | Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. | 2012 | Transplantation | pmid:22960763 |
| Thomas PG et al. | Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. | 2007 | Transplantation | pmid:17565326 |
| Inamura N et al. | Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. | 1988 | Transplantation | pmid:2447690 |
| Peng Y et al. | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. | 2013 | Transplantation | pmid:23263506 |
| Kuypers DR et al. | Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. | 2013 | Transplantation | pmid:23263559 |
| Shapiro R et al. | Tacrolimus in pediatric renal transplantation. | 1996 | Transplantation | pmid:8990356 |
| Ko S et al. | The pharmacokinetic benefits of newly developed liposome-incorporated FK506. | 1994 | Transplantation | pmid:7526494 |
| White M et al. | Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. | 2006 | Transplantation | pmid:17006323 |
| Katz IA et al. | Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. | 1991 | Transplantation | pmid:1716801 |
| Inomata Y et al. | The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. | 1996 | Transplantation | pmid:8600632 |
| Foster RD et al. | Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. | 2003 | Transplantation | pmid:14508367 |